Related Experiment Video
Updated: May 27, 2026
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Response to interferon-Beta treatment in afro-caribbeans with multiple sclerosis
S Jeannin1, R Deschamps, N Chausson
1Department of Neurology, Pierre Zobda-Quitman Hospital, Fort-de-France, 97261 Martinique, French West Indies, France.
Multiple Sclerosis International
|November 19, 2011
Summary
Interferon-beta (INFB) shows limited efficacy in controlling multiple sclerosis (MS) in Afro-Caribbean patients, who often experience a more severe disease course. This suggests a need for alternative treatments for this demographic.
Area of Science:
- Neurology
- Immunology
- Genetics
Background:
- Multiple sclerosis (MS) disproportionately affects patients of African ancestry, presenting with a more aggressive disease course.
- These patients may exhibit resistance to standard treatments like interferon-beta (INFB).
Purpose of the Study:
- To evaluate the effectiveness of interferon-beta (INFB) in treating treatment-naive Afro-Caribbean (AC) patients with clinically definite multiple sclerosis (MS).
Main Methods:
- Utilized European Database for Multiple Sclerosis (EDMUS) data from 2003-2010.
- Analyzed 76 treatment-naive Afro-Caribbean MS patients (59F/17M).
- Assessed annual relapse rate, exacerbation-free proportion at 48 weeks, and time to first relapse post-INFB initiation.
Main Results:
- The annual relapse rate decreased by 35.6% (from 1.29 to 0.83) after two years of INFB treatment.
- 46.2% of patients remained relapse-free at 48 weeks.
- The median time to the first relapse was 52 weeks.
Conclusions:
- Interferon-beta (INFB) demonstrates insufficient efficacy in managing multiple sclerosis (MS) for many Afro-Caribbean patients.
- The findings highlight a significant challenge given the worse prognosis of MS in this population, necessitating further research into alternative therapeutic strategies.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...